Aerie Pharmaceuticals Financials

AERIDelisted Stock  USD 15.25  0.01  0.07%   
Based on the key indicators related to Aerie Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Aerie Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
With this module, you can analyze Aerie financials for your investing period. You should be able to track the changes in Aerie Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Aerie Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aerie Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Aerie Pharmaceuticals' assets may result in an increase in income on the income statement.
Evaluating Aerie Pharmaceuticals' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Aerie Pharmaceuticals' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Aerie Pharmaceuticals' relative financial performance

Chance Of Distress

Over 100

 
100  
 
Zero
Dangerous
Aerie Pharmaceuticals has more than 100 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Aerie Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Aerie Pharmaceuticals' odds of distress score SHOULD NOT be confused with the real chance of Aerie Pharmaceuticals filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Aerie is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Aerie Pharmaceuticals' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Aerie Pharmaceuticals' official financial statements usually reflect Aerie Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aerie Pharmaceuticals. For example, before you start analyzing numbers published by Aerie accountants, it's critical to develop an understanding of what Aerie Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Aerie Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerie Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aerie Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aerie Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Aerie Pharmaceuticals' management manipulating its earnings.

Aerie Pharmaceuticals Company Summary

Aerie Pharmaceuticals competes with Infosys, Ziff Davis, Beyond, Nextplat Corp, and Sapiens International. Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 376 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS00771V1089
Business Address4301 Emperor Boulevard,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.aeriepharma.com
Phone919 237 5300
CurrencyUSD - US Dollar
You should never invest in Aerie Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Aerie Stock, because this is throwing your money away. Analyzing the key information contained in Aerie Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Aerie Pharmaceuticals Key Financial Ratios

Generally speaking, Aerie Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Aerie Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Aerie Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Aerie Pharmaceuticals reports annually and quarterly.

Aerie Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aerie Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aerie Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aerie Pharmaceuticals competition to find correlations between indicators driving Aerie Pharmaceuticals's intrinsic value. More Info.
Aerie Pharmaceuticals is number one stock in number of shares shorted category among related companies. It is number one stock in cash and equivalents category among related companies creating about  121.16  of Cash And Equivalents per Number Of Shares Shorted. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aerie Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aerie Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aerie Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Aerie Pharmaceuticals Market Pulse

 Quote15.25
 Change(%)  0.07 
 Change0.01 
 Open15.24
 Low15.24
 High15.25
 Volume0
 ExchangeNASDAQ

About Aerie Pharmaceuticals Financials

What exactly are Aerie Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Aerie Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Aerie Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Aerie Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aerie Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aerie Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Aerie Pharmaceuticals Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Aerie Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Aerie has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Aerie Pharmaceuticals' financials are consistent with your investment objective using the following steps:
  • Review Aerie Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Aerie Pharmaceuticals' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Aerie Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Aerie Pharmaceuticals' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Aerie Pharmaceuticals March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Aerie Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aerie Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aerie Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Aerie Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aerie Pharmaceuticals's daily price indicators and compare them against related drivers.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Aerie Stock

If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance